Skip to main content
Premium Trial:

Request an Annual Quote

Daiichi Licenses Inpharmatica s ADME Platform Admensa Interactive

NEW YORK, June 6 (GenomeWeb News) - Daiichi Pharmaceuticals has licensed Inpharmatica's Admensa Interactive, a suite of ADME models and compound prioritization tools, the companies said today.


Daiichi has also made a "significant" yet undisclosed milestone payment to Inpharmatica after the company identified a "novel" drug target using its Chematica services and virtual screening technology.


Inpharmatica said Daiichi is the first Japanese company to license Admensa Interactive. In 2002, Daiichi obtained  a nonexclusive subscription to Inpharmatica's Biopendium protein database.


Chematica and Admensa Interactive are components of PharmaCarta, Inpharmatica's gene-to-candidate platform which integrates biology- and chemistry-based drug discovery activities.